DDX41 and myeloproliferative neoplasm: We applied a targeted myeloid NGS panel to 1930 patients with hematologic malignancies seen at our institution and identified 51 cases (13 MPNs and 38 MDS/AMLs) carrying at least one mutation in DDX41. The 2.6% incidence for DDX41 AML/MDS and MPN patients identified in this study is comparable to the pooled incidence of 3.3% reported in a systematic review of 20 studies on DDX41 mutated myeloid neoplasms (7).